30 minutes for non-DAC Standard dose (DAC) / 1,000 to 2,000 mcg subcutaneously once weekly Standard dose (non-DAC, mod GRF 1-29) / 100 to 300 mcg subcutaneously daily Renal dosing data / no formal pharmacokinetic study in CKD populations Suggested CKD adjustment / reduce starting dose by 25 to 50% and extend intervals Key monitoring / serum IGF-1, eGFR, serum creatinine, fasting glucose every 4 to 6 weeks Regulatory status / investigational
Rezvoglar (insulin glargine-aglr) - Eli Lilly and Company View Rezvoglar information in detail
During perimenopause and menopause, lower estrogen levels can increase insulin resistance, abdominal fat distribution, appetite changes, sleep disruption, and loss of lean muscle mass
Last reviewed: May 29, 2026 Last updated: May 29, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations